Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2020 Nov 1;21(11):3229-3234.
doi: 10.31557/APJCP.2020.21.11.3229.

Comparison of Polymerase Chain Reaction-Restriction Fragment Length Polymorphism, Immunohistochemistry, and DNA Sequencing for the Detection of IDH1 Mutations in Gliomas

Affiliations
Comparative Study

Comparison of Polymerase Chain Reaction-Restriction Fragment Length Polymorphism, Immunohistochemistry, and DNA Sequencing for the Detection of IDH1 Mutations in Gliomas

Rusdy Ghazali Malueka et al. Asian Pac J Cancer Prev. .

Abstract

Background: IDH1 mutation shows diagnostic, prognostic, and predictive value in gliomas. Direct Sanger sequencing is considered the gold standard to detect IDH1 mutation. However, this technology is not available in most neuropathological centers in developing countries such as Indonesia. Immunohistochemistry (IHC) and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) have also been used to detect IDH1 mutation. This study aimed to compare DNA sequencing, IHC, and PCR-RFLP in detecting IDH1 mutations in gliomas.

Methods: Research subjects were recruited from Dr. Sardjito Hospital. Genomic DNA was extracted from fresh or formalin-fixed paraffin-embedded samples of tumor tissue. DNA sequencing, PCR-RFLP and IHC were performed to detect IDH1 mutation. Sensitivity, specificity, and accuracy of PCR-RFLP and IHC were calculated by comparing them to DNA sequencing as the gold standard.

Results: Among 61 recruited patients, 13 (21.3%) of them carried a mutation in codon 132 of the IDH1 gene, as shown by DNA sequencing. PCR-RFLP and DNA sequencing have a concordance value of 100%. Meanwhile, the concordance value between IDH1 R132H IHC and DNA sequencing was 96.7%. The sensitivity, specificity, positive predictive values, negative predictive values, and accuracy for PCR-RFLP were all 100%. On the other hand, the sensitivity, specificity, and accuracy of IHC were 92.3%, 97.9%, and 96.7%, respectively.

Conclusion: This study showed that both PCR-RFLP and IHC have high accuracy in detecting IDH1 mutation. We recommend a combination of PCR-RFLP and IHC to detect IDH1 mutation in resource-limited settings.<br />.

Keywords: DNA Sequencing; Glioma; IDH1 gene; PCR–RFLP; immunuhistochemistry.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Nucleotide Sequencing Results Showing Wild-Type (A) and Mutant (B) IDH1 Genes
Figure 2
Figure 2
Gel Electrophoresis of PCR–RFLP Product. Fragment of IDH1 gene digested with Pvu1 enzyme. Lane M, 100bp DNA ladder; Lane 1, undigested product; Lane 2, showing one band at 237-bp, indicates a wild type; lane 3, showing double bands at 261-bp and 237-bp, indicates a mutation in codon 132 of the IDH1 gene
Figure 3
Figure 3
Immunohistochemistry Result of IDH1 R132H (400x). Negative expression is determined as absolutely no reactivity detected (A), or only positively stained in either cytoplasm or nuclei (picture not shown) or in <10% of overall tumor cells. Positive expression is determined as both, nuclei and cytoplasm, are stained brown in >10% of overall tumor cells (B)

Similar articles

Cited by

References

    1. Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. Neuro Oncol. 2013;15:718–26. - PMC - PubMed
    1. Arita H, Narita Y, Matsushita Y, et al. Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas. Brain Tumor Pathol. 2014;32:22–30. - PubMed
    1. Bujko M, Kober P, Matyja E, et al. Prognostic value of IDH1 mutations identified with PCR–RFLP assay in glioblastoma patients. Mol Diagn Ther. 2010;14:163–9. - PubMed
    1. Capper D, Weissert S, Balss J, Habel A, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2010;20:245–54. - PMC - PubMed
    1. Catteau A, Girardi H, Monville F, et al. A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma. Acta Neuropathol Com. 2014;2:58. - PMC - PubMed

Publication types

MeSH terms